



Committee/Group 'Triple A' Chair's Report

| | | | |
|-------------------------|-----------------------|-------------------|-------------|
| Name of Committee/Group | Performance Committee | Reporting to: | Trust Board |
| Date of the meeting: | 19 February 2020 | Parent Committee: | Trust Board |
| Chair: | Geoff Broadhead | Quorate (Y/N) | Y |

| Agenda Item: | RAG | Key Points | Actions Required | Action Lead | Expected Date for Completion |
|-------------------------------|-----|--|--|-------------|------------------------------|
| TCC Finance Report | | The Committee noted that at the time of the report, the new building was within budget and further acknowledged that this is a significant achievement given the overall cost of the capital scheme. | Financial performance reporting to continue. | JA | Ongoing |
| Integrated Performance Report | | <p>The Performance Committee welcomed the progress made in the development of the IPR and the migration towards a more automated process.</p> <p>The Committee noted the update to the associated action plan and agreed to extend the end date for incorporating Corporate Services into the IPR schedule to 31 March 2020.</p> | Further development to continue as per the agreed action plan. | JSp | Ongoing |

| Agenda Item: | RAG | Key Points | Actions Required | Action Lead | Expected Date for Completion |
|----------------------------------|-----|--|--|-------------|------------------------------|
| Directorate Performance Reviews | | Haemato-Oncology: A delay has been identified relating to the implementation of e-Prescribing for inpatients due to an unexpected malfunction in the system resulting in a risk that some medicines that have been stopped are pulled into the nursing record. | Meditech are investigating this matter. | NA & LF | 31 March 2020 |
| Finance Report – Month 10 | | The Committee noted the Trust has delivered 90% of its CIP requirement to the end of December 2019 with a forecast to deliver the full £1.8m by March 2020. | Work remains ongoing to consider ways of translating non-recurrent CIP saving to recurrent. | JA | Ongoing |
| Finance Report Month 10 | | The agency expenditure metric remains below plan due to continued operational requirements; this has resulted in our agency rating remaining at 4 (highest risk). However, NHSI recognise the position and due to the underlying positive financial position, we continue to be rated as 'Segment 1'. | Continue with recruitment drive to fill consultant vacancies. A separate paper at February Board around current challenges relating to this. | JT/SK/GMs | Ongoing |
| Finance and Operational Planning | | NHSI's Operational Planning and Contracting Guidance 2020-21 was received on 31 January 2020. Key messages related to: <ul style="list-style-type: none"> • Commitment to system planning with all working towards an Integrated Care System by 2021. • Ongoing clinically led review of NHS Access standards with a new diagnostic target of 28 days • Improvement in retention and the redesign of workforce models. | Complete planning timetable to final submission on 29 April 2020 | JT | April 2020 |

| Agenda Item: | RAG | Key Points | Actions Required | Action Lead | Expected Date for Completion |
|--|-----|--|--|-------------|------------------------------|
| | | <ul style="list-style-type: none"> In addition to the planning guidance we received a letter from NHSI/E Regional Director which outlined an increase in the Trust's expected control total surplus of £445K for 2020/21. | | | |
| CPL Performance | | The Committee noted positive performance with a very positive patient survey and a strong financial position. | Report on outcome of the GPHC Inspection due week commencing 24 February 2020 | BZ | March 2020 |
| PropCare – Reporting on Performance | | <p>Service Level Agreements negotiations remain ongoing with Aintree.</p> <p>Utilisation of the Wirral site by WUTH: this remains ongoing and the uncertainty of usage by third parties makes it difficult for the trust to complete site plans.</p> | Continue to pursue both Aintree and WUTH for decisions. | PC | March 2020 |
| Joint Venture – Reporting on Performance | | The Committee noted the continued positive financial performance. | Negotiations continue in relation to the renewal of the Joint Venture Agreement which is due to be discussed at Board in February. | JT | 26 February 2020 |
| Performance Risk Register | | The Committee discussed the decision made within the Risk Management Committee to enable further work to be carried out on the content of the risk registers. | This will be further discussed at Quality Committee on 20 February 2020 | LB | 20 February 2020 |

| | |
|--|--|
| | ALERT the Committee on areas of non-compliance or matters that need addressing urgently |
| | ADVISE the Committee on any on-going monitoring where an update has been provided to the sub-committee and any new developments that will need to be communicated or included in operational delivery |
| | ASSURE the Committee on any areas of assurance that the Committee/Group has received |